1. Базин И.С. Современная тактика комбинированного лечения метастатического рака толстой кишки. Труд. пац. 2006; 11.
2. Давыдов М.Н., Аксель Е.Н. Статистика злокачественных новообразований в России и странах СНГ (состояние онкологической помощи, заболеваемость и смертность). М., 2002.
3. Adam R et al. Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases Ann Surg Oncol 2001; 8: 347–53.
4. Van Cutsem E et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial» ASCO 2007. Abstract 4000.
5. Van Cutsem E, Lang I, D'haens G et al. K-RAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26: (Suppl.): abstr 2.
6. Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study, 2007 ASCO Annual Meeting Proceedings. Part I. J Clin Oncol 2007; 25 (Suppl. 18): 4035.
8. Bokemeyer С, Bondarenko I, Hartmann JT et al. K-RAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26: (Suppl.): abstr 4000.
9. Segart S et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. JDDG 2005; 3: 599–606.
10. Adam R et al. Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival. Ann Surg 2004; 240 (4): 644–58.
Авторы
М.И.Секачева, О.Г.Скипенко
Отделение хирургии печени, желчных протоков и поджелудочной железы РНЦХ им. акад. Б.В.Петровского РАМН, Москва